No connection

Search Results

ABBV vs AGIO

ABBV
AbbVie Inc.
NEUTRAL
Price
$219.26
Market Cap
$387.52B
Sector
Healthcare
AI Confidence
68%
AGIO
Agios Pharmaceuticals, Inc.
BEARISH
Price
$27.85
Market Cap
$1.63B
Sector
Healthcare
AI Confidence
85%

Valuation

P/E Ratio
ABBV
163.63
AGIO
--
Forward P/E
ABBV
15.42
AGIO
-5.74
P/B Ratio
ABBV
-146.66
AGIO
1.36
P/S Ratio
ABBV
6.5
AGIO
30.2
EV/EBITDA
ABBV
15.27
AGIO
-1.75

Profitability

Gross Margin
ABBV
71.46%
AGIO
0.0%
Operating Margin
ABBV
35.5%
AGIO
-608.89%
Profit Margin
ABBV
4.0%
AGIO
0.0%
ROE
ABBV
137.96%
AGIO
-30.2%
ROA
ABBV
9.59%
AGIO
-19.93%

Growth

Revenue Growth
ABBV
9.1%
AGIO
86.1%
Earnings Growth
ABBV
-88.7%
AGIO
--

Financial Health

Debt/Equity
ABBV
--
AGIO
0.03
Current Ratio
ABBV
0.72
AGIO
11.46
Quick Ratio
ABBV
0.47
AGIO
10.53

Dividends

Dividend Yield
ABBV
3.05%
AGIO
--
Payout Ratio
ABBV
490.15%
AGIO
0.0%

AI Verdict

ABBV NEUTRAL

The Advanced Deterministic Scorecard reveals a mixed health profile with a Piotroski F-Score of 4/9 indicating stable but not strong fundamentals, while the absence of an Altman Z-Score prevents a clear distress risk assessment. Despite robust operating margins and consistent revenue growth, the company faces significant headwinds from negative earnings growth, an extremely high P/E ratio, and a dangerously elevated payout ratio. Strong historical price performance and analyst buy sentiment are counterbalanced by bearish insider activity and deteriorating profitability trends. The stock appears to trade at a substantial premium to its intrinsic value, suggesting limited margin of safety.

Strengths
High operating margin (35.50%) indicating strong pricing power and cost control
Consistent revenue growth (9.10% YoY) outpacing sector average
Strong track record of earnings surprises (22 out of 25 quarters beat estimates)
Risks
Extremely high P/E ratio (163.63) vs forward P/E (15.42), suggesting potential overvaluation on trailing basis
Earnings growth collapsing (YoY: -88.70%, Q/Q: -88.10%) indicating severe profitability deterioration
Unsustainable dividend payout ratio (490.15%) threatening dividend security
AGIO BEARISH

AGIO's Advanced Deterministic Scorecard reveals severe financial distress: a Piotroski F-Score of 1/9 indicates poor operational and financial health, while the absence of an Altman Z-Score raises red flags for potential bankruptcy risk. Despite strong revenue growth of 86.1% YoY, the company reports a 0.00% profit margin, negative operating margin of -608.89%, and negative ROE of -30.20%, signaling deep operational inefficiencies. Insider selling activity totaling $2.06M over six months, with multiple officer sales, underscores lack of confidence from within the organization. The stock trades at a premium valuation (Price/Sales of 30.20) with no earnings or cash flow support, and its 52-week high is 65% above current levels, indicating overvaluation relative to fundamentals.

Strengths
Strong revenue growth of 86.1% YoY, indicating market traction and product demand
High analyst consensus with a 'buy' recommendation from 8 analysts
Extremely low debt/equity ratio of 0.03, suggesting minimal leverage risk
Risks
Piotroski F-Score of 1/9 indicates severe financial deterioration and weak operational performance
Negative operating margin (-608.89%) and zero profit margin reflect unsustainable business model
Insider selling of 35,569 shares ($2.06M value) signals internal skepticism

Compare Another Pair

ABBV vs AGIO: Head-to-Head Comparison

This page compares AbbVie Inc. (ABBV) and Agios Pharmaceuticals, Inc. (AGIO) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile